课题基金 / 基金详情

ECT current amplitude and medial temporal lobe engagement

ECT current amplitude and medial temporal lobe engagement
ECT 电流幅度和内侧颞叶接合
批准号:
9228452
负责人:
Christopher C Abbott
金额:
$52.23万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-26 至 2020-07-31

项目摘要

项目成果

Christopher C Abbott的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
1. Project Summary/Abstract Electroconvulsive therapy (ECT) remains the gold-standard treatment for patients with depressive episodes. During a typical four-week ECT series, most depressive episodes remit, and formerly suicidal or psychotically depressed patients will resume their premorbid levels of functioning. Independent of the antidepressant effect of ECT, many patients experience debilitating but transient cognitive effects such as attention and memory def- icits. These unwanted side effects are particularly troubling for older patients who are more likely to have exist- ing cognitive deficits. Both the stimulus delivery (electrode placement, pulse amplitude, and pulse width) and seizure induction appear to work in synergy, but the underlying mechanism of action for successful response has yet to be fully elucidated. Moreover, further work is needed to understand the relationship between clinical improvement and cognitive impairment. This investigation will examine the clinical and neurocognitive impact of targeted medial temporal lobe engagement as a function of pulse amplitude, one of several variable factors influencing the ECT charge. The ECT charge is measured in millicoulombs (mC) and derived from multiplying pulse train duration, pulse-pair frequency, pulse width, and pulse amplitude. Pulse amplitude determines the induced electric field strength in the brain and is presently fixed at 900 milliamperes (mA) with no clinical or scientific justification. The central hypothesis of this investigation is that the optimal pulse amplitude for an indi- vidual patient will enhance neuroplasticity (clinical response) while minimizing the disruption of dominant hemi- sphere hippocampal cognitive circuitry (resulting in cognitive stability). Our preliminary data informs the dosage range between 600 and 800 mA. Pulse amplitudes outside of this range compromise efficacy (500 mA) or may increase risk of cognitive impairment (900 mA). The first aim of this investigation will identify the electric field strength and neuroplasticity associated with clinical response. Critically, this aim will establish the neuroplas- ticity threshold, which is defined as the electric field strength necessary to induce neuroplasticity. The second aim will detect the neural correlates of ECT-mediated cognitive changes, which may be related to disrupted dominant hemisphere long-term potentiation. The third aim will use data-driven dual regression to predict the optimal pulse amplitude for an individual patient. This contribution will be significant because the electric field, when manipulated by pulse amplitude, can subsequently maximize hippocampal neuroplasticity (efficacy) and minimize disrupted connectivity (cognitive stability) thus improving clinical outcomes. 2 !
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
Electroconvulsive therapy amplitude titration for improved clinical outcomes in late-life depression
Electroconvulsive therapy amplitude titration for improved clinical outcomes in late-life depression
海外基金